EffRx Inc., Nycomed Group A/S deal

The companies added new territories to Nycomed's exclusive rights to develop and commercialize EffRx's EX101 to treat musculoskeletal diseases, except hypercalcemia of malignancy. Nycomed now has rights to develop and commercialize the effervescent formulation of alendronate worldwide, excluding the U.S., Japan, South Africa and "a few other minor markets." EffRx is eligible to receive an additional $15 million in upfront payments and milestones for a total of $74 million, plus double-digit royalties. EX101 is in pivotal bioequivalence testing in Germany to treat osteoporosis, with data expected next quarter. Nycomed expects to submit for regulatory approval in Europe by year end. ...